negative mode datasets were combined to yield 569 features for the 66 samples. Using the PLS toolbox 8.1.1 (Eigenvector Research Inc.) within MATLAB R2012b, a PCA model built using those 66 samples demonstrated class separation between RCC and control when viewing the score plot of the first two principle components. The features in the dataset were auto-scaled prior to building the model. The dataset was also used to build a supervised orthogonalized partial least squares discriminant analysis (oPLS-DA) model to classify samples with internal cross validation. The features in the dataset were auto-scaled prior to building the model. Cross validation was performed ten times with random subset approach that utilized 1/6 of the dataset to evaluate the model training based on remaining 5/6 of the dataset.
INTRODUCTION AND OBJECTIVES:
Renal cell carcinoma (RCC) is the most common and lethal malignancy of the kidney. Distinction of the RCC from the benign renal tumor is still a clinical challenge. Urine metabolomics has been used to identify biomarkers for clinical diseases.
METHODS: In present study, we explored urine metabolome in a cohort of 36 patients with renal tumor (24 RCC and 12 benign renal tumor), and 44 health control using liquid chromatography coupled with high resolution mass spectrometry (LC-MS).
RESULTS: Metabolic profiling of urine could significantly differentiate RCC from the health control and the benign control. Metabolic pathways, including lysine metabolism and phenylalanine metabolism were found to be disturbed in RCC group. Steroid hormone biosynthesis was significant differential between benign and RCC. RCC biomarker was further explored. A metabolite panel consisting of cortolone, testosterone and L-2-aminoadipate adenylate were discovered to have good prediction for RCC from benign with AUC of 0.868 for 10 fold cross-validation. And the panel of aminoadipic acid, 2-(Formamido)-N1-(5-phospho-D-ribosyl)acetamidine and alpha-NPhenylacetyl-L-glutamine could distinct RCC from the health control with AUC of 0.841 10 fold cross-validation.
CONCLUSIONS: This pilot study suggests that urine metabolomics may be useful in differentiating RCC from the control and the benign renal tumor. Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 THE JOURNAL OF UROLOGY â e1197
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MP88-03 USE OF URINARY METABOLOMICS TO IDENTIFY HIGH-RISK CLEAR CELL RENAL CELL CARCINOMA
Mohit Gupta*, Hiten Patel, Alice Semerjian, Michael Gorin, Michael Johnson, Mohamad Allaf, Phillip Pierorazio, Baltimore, MD INTRODUCTION AND OBJECTIVES: Metabolomics offers the ability to exploit the unique metabolic dysregulation inherent in known pathways of renal cell carcinoma pathogenesis to help guide clinical management. While metabolomic pathways and signatures have been studied of a variety of cancers, the signature of urine of patients with RCC has not been well established. We consequently interrogated distinct urinary pathway-level metabolic shifts in patients following surgical excision of renal masses to differentiate metabolic profiles of highrisk clear cell RCC (ccRCC) from indolent and benign tumors.
METHODS: Patients undergoing surgery for non-metastatic RCC were enrolled in an IRB-approved, institutional biorepository and donated urine samples prior to surgery. Patients 0 pathology was indexed as high-risk (HR), defined as high-grade (Grade III-IV) and/or locally-advanced (pT3 or higher) ccRCC; indolent, defined as pT1-T2 and low-grade (Grade I-II) ccRCC; or benign. Capillary electrophoresis mass spectrometry was utilized to process urine samples in a highthroughput fashion to identify distinctive metabolomic profiles indicative of the three pathologies. Sixty-nine targeted metabolites were detected and quantified; principal components analysis and heatmaps were generated. Differences were analyzed using Welch 0 s t-test. RESULTS: A total of 66 urine specimens were included in our analysis: 30 (45.4%) were from patients with HR RCC, 19 (28.8%) from patients with indolent disease, and 17 (25.8%) from patients with benign pathology. Patients with indolent lesions had higher concentrations of the following unique amino acids compared to benign lesions (p<0.01): Phe (þ42.4%), Tyr (þ52.2%), Trp (þ42.7%) and Lys (þ66%). Concentrations of several unique metabolites differed between benign and HR RCC lesions (p<0.01): Hypoxanthine (-42%), Threonic Acid (þ26%), EAP (þ133%), and Glycerol-3-phosphate (þ110%). HR RCC had smaller concentrations of the following metabolites versus indolent lesions (p<0.01): Betaine (-63%), Hydrouracil (-36%), N-Ac Gln (-56%), Histidine (-42%), and 2-aminoisobutyrate (-47%).
CONCLUSIONS: Given the prevalent metabolic rearrangements in RCC, use of urinary metabolomics represents a promising biomarker that can not only distinguish ccRCC from benign tumors, but also risk-stratify dangerous cancers from indolent ones by identifying specific metabolic profiles.
Source of Funding: None
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